Ascendiant Capital Markets Estimates CNSY Q3 Earnings

Plus Therapeutics, Inc. (NASDAQ:CNSY) – Equities researchers at Ascendiant Capital Markets cut their Q3 2026 EPS estimates for shares of Plus Therapeutics in a research note issued to investors on Thursday, September 10th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will earn ($0.98) per share for the quarter, down from their previous forecast of ($0.92). The consensus estimate for Plus Therapeutics’ current full-year earnings is ($3.76) per share. Ascendiant Capital Markets also issued estimates for Plus Therapeutics’ Q4 2026 earnings at ($0.91) EPS, FY2026 earnings at ($4.40) EPS, Q1 2027 earnings at ($0.78) EPS, Q2 2027 earnings at ($0.78) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($3.17) EPS.

CNSY has been the subject of several other reports. Weiss Ratings began coverage on Plus Therapeutics in a research note on Tuesday, August 4th. They issued a “sell (e+)” rating for the company. Zacks Research upgraded Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 1st. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Plus Therapeutics has an average rating of “Reduce”.

Plus Therapeutics Stock Performance

CNSY opened at $2.04 on Thursday. The company has a market capitalization of $15.48 million, a price-to-earnings ratio of -0.61 and a beta of 1.39. Plus Therapeutics has a 1-year low of $2.00 and a 1-year high of $23.42.

Plus Therapeutics (NASDAQ:CNSY) last announced its earnings results on Friday, August 14th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.35). Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%. The business had revenue of $0.41 million for the quarter.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.